Alesta Therapeutics

Established in 2021 and based in Leiden, Netherlands, Alesta Therapeutics operates as a biotechnology company that researches and develops small molecules for rare diseases. In January 2025, Alesta Therapeutics raised EUR 65 million in series A funding co-led by investors Frazier Lifesciences Acquisition Corporation and Droia Ventures, with participation from other investors Novartis Venture Fund, RTW Investments, etc. The firm as of Jnauary 2025, is led by its CEO, Ilan Ganot. The company focuses on the development of innovative oral small molecules intended for the treatment of rare diseases.

Their core products include ALE1, addressing hypophosphatasia (HPP), and ALE2, targeting Charcot-Marie-Tooth disease (CMT). ALE1 is designed to treat the full spectrum of HPP symptoms, which can affect bone and dental health, while ALE2 aims to mitigate chronic neurotoxicity associated with specific genetic alterations in CMT. These products are currently in the pre-clinical and clinical development stages, with ALE1 expected to enter clinical studies in 2025. Alesta Therapeutics, as of January 2025, serves patients in the United States and Europe, specifically targeting a population of approximately 50,000 individuals with HPP in the US and 75,000 in Europe, alongside about 126,000 affected by CMT in the US and 2.

6 million worldwide. The company plans to utilize the January 2025 funding to expand its operations and enhance its research and development efforts.